The editorial article is devoted to the key research directions presented in the fourth issue of the journal for 2026. The materials of the issue reflect the development of contemporary obstetric and gynecological science toward personalized risk assessment, digital prediction, and interdisciplinary interpretation of clinical, laboratory, instrumental, molecular, genetic, and immunological data. Particular attention is paid to the prediction of pregnancy complications, including preeclampsia, placenta-associated complications after SARS-CoV-2 infection, cervical remodeling, and reproductive outcomes in assisted reproductive technology programs. The article also discusses surgical treatment of genital prolapse, correction of iron deficiency states in abnormal uterine bleeding, immune mechanisms of tumor progression, sexual rehabilitation after treatment for gynecologic cancer, hemostatic disorders in recurrent pregnancy loss, genetic and epigenetic aspects of polyendocrine metabolic ovarian syndrome, management of patients of advanced reproductive age, treatment of epilepsy in women of reproductive age, and pregnancy in autoimmune diseases. The need for critical assessment of prognostic models, novel biomarkers, and publication integrity is separately emphasized as an essential prerequisite for trust in contemporary scientific writing.

Introduction. Laparoscopic sacropexy is widely used for the treatment of pelvic organ prolapse (РОР). The safety and efficacy of this procedure have been studied in many countries, but the causes of recurrence are not fully understood.
Aim: to evaluate frequency of adverse outcomes 12 months postoperative laparoscopic sacropexy and to identify associated risk factors.
Materials and Methods. The observational prospective controlled non-randomized study was conducted at the Surgical Clinic of Azerbaijan Medical University (AMU). A total of 235 patients who underwent surgery at the clinic from 2013 to 2023 were included in a consecutive observational cohort. All patients were examined preoperatively and at 1, 6, and 12 months postoperatively using the Pelvic Organ Prolapse Quantification (POP-Q) system. All major postoperative complications and recurrences were recorded as they occurred.
Results. During the 12-month follow-up, the overall recurrence rate was 29.5 ± 2.9 %. The need for repeat surgery peaked among patients with a preoperative Ba measurement of −2 cm (12.5 ± 8.2 %). A high rate of reoperations was also observed in patients with a preoperative Ba measurement of +3 cm (11.9 ± 6.9 %; 95 % confidence interval (CI) = 2.1–21.8 %). Reoperation rates below 2.1 % were observed in women with diverse situational factors – age < 50 years, premenopausal status, body mass index (BMI) < 25 kg/m², baseline Ba −2 and −1, etc. The maximum frequency of apical recurrences was 11.5 ± 3.6 % (95 % CI = 4.3–18.7 %) and occurred in patients whose preoperative D measurement ranged from −3 to +3 cm.
Conclusion. The recurrence rate after laparoscopic sacropexy varies and depends on the clinical profile of the patients. The risk of postoperative recurrence after laparoscopic sacropexy increases significantly with patient age, higher body mass index, onset of menopause, and unfavorable preoperative prolapse characteristics according to the Pelvic Organ Prolapse Quantification (POP-Q) system

Introduction. SARS-CoV-2 infection during gestation is associated with dramatically increased incidence of major obstetrical syndromes (МOS).

Aim: to evaluate a combined impact of COVID-19 contracted during the first or second trimester of pregnancy, baseline somatic history as well as the VDR gene rs2228570 polymorphism on МOS risk manifestation.

Materials and Methods. This study involved 299 pregnant women. Initially, the participants were allocated into two groups: the primary cohort comprised patients who underwent SARS-CoV-2 infection during the first or second trimester of gestation (Group 1, n = 146), while the control group consisted of pregnant women with no history of infectious pathology (Group 2, n = 153). Based on the pattern of gestational outcomes, the cohorts were stratified into subgroups: 1a (МOS manifestation, n = 40) and 1b (physiological outcomes, n = 106) within the infected cohort; 2a (МOS presence, n = 16) and 2b (uncomplicated gestation, n = 137) within the control group. Molecular genetic testing of the VDR gene rs2228570 locus was performed by real-time PCR, followed by statistical data processing.

Results. COVID-19 contracted during pregnancy increased the overall МOS incidence by 2.6-fold (p = 0.0002), with predominance of severe preeclampsia (p = 0.018; odds ratio (OR) = 5.55). The manifestation of placenta-associated complications was linked to the presence of respiratory (p = 0.018) and digestive (p = 0.022) system diseases. The VDR gene rs2228570 locus did not influence the risk of SARS-CoV-2 infection during gestation (p = 0.297) but acted as a significant МOS predictor of placental decompensation in the post-COVID period (p = 0.0007). The presence of the AG genotype increased the risk of MOS development by 4.2-fold (95 % confidence interval (CI) = 1.47–11.81; p = 0.0056), whereas the GG genotype elevated it by 7.3-fold (95 % CI = 2.22–23.93; p = 0.0009).

Conclusion. The VDR gene rs2228570 polymorphism does not determine the risk of SARS-CoV-2 infection during pregnancy; however, under post-infectious conditions, the carriage of the G allele may serve as МOS predictor developing in concomitant respiratory and digestive system diseases.

Aim: to systematically compare the discrimination and calibration of eight machine learning (ML) algorithms with the Fetal Medicine Foundation (FMF) competing risks algorithm for first-trimester prediction of early-onset (< 34 weeks), late-onset (> 34 weeks), severe, and preterm (< 37 weeks) preeclampsia (PE) by assessing the incremental value of markers with a nested model architecture (M0 [model includes only clinical and anamnestic data] → M2 [model supplemented with biophysical markers] → M4 [model supplemented with biochemical markers]) and external validation in an independent dataset (n = 7,581).

Materials and Methods. A retrospective cohort study (TRIPOD 2b + 3) was conducted. Development: a development cohort (n = 7,581) with 10-fold stratified cross-validation. External validation: an independent cohort (n = 7,581). A total of 96 benchmark configurations were developed (8 algorithms × 3 predictor levels × 4 outcomes): M0 – 15 clinical and history-based factors; M2 – adding mean arterial pressure (MAP) and uterine artery pulsatility index (UtAPI); M4 – adding placental growth factor (PlGF) and pregnancy-associated plasma protein-A (PAPP-A). Evaluation metrics: AUC-ROC (Area Under the Receiver Operating Characteristic curve), calibration (O:E ratio (observed-to-expected ratio), calibration slope, Brier score), net reclassification improvement (NRI). integrated discrimination improvement (IDI), decision curve analysis (DCA), and SHapley Additive exPlanations (SHAP).

Results. At the M4 level, logistic regression demonstrated the highest discrimination: early-onset PE – AUC = 0.976 (an optimistic estimate with EPV (events per variable) = 3.7; detection rate 92.9 % at 10 % FPR (false positive rate); late-onset PE – 0.837; severe PE – 0.885, preterm PE – 0.908; with the most robust calibration among all algorithms (O:E = 0.99–1.00), confirmed in the external cohort for M0 and M2 levels. Nonlinear algorithms and stacking did not achieve a significant advantage. For preterm PE (the target outcome of the FMF algorithm), logistic regression and FMF posterior were comparable in discrimination (ΔAUC = +0.002; p > 0.05) level, with the former showing superior calibration in the Russian population. For late-onset PE (the dominant disease phenotype not modeled by FMF), logistic regression provided significantly better risk stratification (AUC = 0.837 vs. 0.807; p < 0.05). The FMF algorithm exhibited miscalibration: risk overestimation for its target outcomes (O:E = 0.55 for early-onset PE) and structural underestimation for non-target outcomes (O:E = 2.84 for late-onset PE). Biophysical markers were critical for early-onset PE, whereas biochemical markers were critical for late-onset PE; this pattern was consistent across algorithms. External validation confirmed robust discrimination at the M0 level (AUC = 0.790–0.823; n = 7,581) and M2 level (AUC = 0.801–0.931; n = 4,080); results at the M4 level (n = 1,010; 11–40 events) are preliminary.

Conclusion. Nonlinear ML algorithms do not outperform logistic regression, which demonstrated the most robust calibration confirmed by external validation at the M0 and M2 levels. Logistic regression with an M0 → M2 → M4 architecture is recommended for clinical decision support systems in first-trimester PE screening. The FMF algorithm requires population-specific recalibration for its target outcomes and is structurally not designed to predict late-onset PE.

Introduction. The high prevalence of iron deficiency in women with abnormal uterine bleeding (AUB) requires optimizing therapeutic approaches.

Aim: to evaluate the clinical efficacy and safety of therapy with iron fumarate in combination with folic acid in reproductiveage patients with AUB complicated by iron deficiency anemia (IDA) and latent iron deficiency (LID).

Materials and Мethods. There were retrospectively analyzed 75 outpatient patient records (2021–2025) stratified as follows: 40 patients with IDA (hemoglobin level < 120 g/L) and 35 patients with LID (ferritin content < 30 ng/ml). Patients received iron fumarate 163.56 mg (equivalent to 50 mg iron) + folic acid 540 μg (equivalent to 500 μg dry matter) for a course of 12 weeks. Treatment efficacy was assessed according to the hemoglobin, ferritin and sideropenic syndrome severity scales.

Results. A statistically significant increase in red blood parameters in all groups (p < 0.001) was recorded during treatment. The following changes were found: in IDA group median hemoglobin and ferritin level increased from 110 to 123 g/L and from 12 to 21 ng/ml, respectively; in LID group – from 123 to 136 g/L and from 22 to 34 ng/ml, respectively.

Conclusion. Combination therapy with iron and folic acid preparations demonstrates high efficacy and safety in correcting anemic and sideropenic syndromes in patients with AUB, which justifies the expediency of its inclusion in the management standards for this category of patients.

Aim: to characterize cervical maturity phenotypes identified by cluster analysis of ultrasound cervicometry and elastography parameters through evaluation of local immunological and microbiological markers associated with cervical remodeling.

Materials and Methods. A single-center prospective cohort study with 82 pregnant women in the third trimester was conducted to assess biomechanical, immunological, and microbiological characteristics of the cervix. Compression cervical elastography was performed by assessing hardness ratio (HR), elasticity contrast index (ECI), internal os strain (IOS), and external os strain (EOS). Quantitative assessment by polymerase chain reaction (PCR) of the cervical canal microbiocenosis and analysis of mRNA expression of innate immunity genes were also performed.

Results. There were identified three cervical maturity phenotypes characterized by a progressive decrease in tissue stiffness (HR), cervical shortening, and an increase in the elasticity contrast index (ECI) (p < 0.05). A significant decline in the expression of interleukin-18 (IL-18), GATA binding protein 3 (GATA3) as well as cluster of differentiation 68 (CD68) marker was observed during the transition from the immature to mature phenotype (p < 0.05). No significant differences in the taxonomic cervical microbiota composition were found among the phenotypes (p > 0.05); however, an increased abundance of non-Lactobacillus flora was associated with reduced cervical length and lower tissue stiffness. Predominantly negative correlations were identified between the abundance of opportunistic microorganisms and the expression levels of immune markers.

Conclusion. Cervical remodeling during pregnancy is associated with decreased local immune activity. Lowered expression of IL-18, GATA3, and CD68 may represent one of the mechanisms initiating inflammation followed by structural remodeling of cervical tissue. Although the microbiota does not determine the maturity phenotype, it may modulate magnitude of immune and biomechanical changes.

Introduction. Infertility is a major reproductive health problem, and in vitro fertilization (IVF) with intracytoplasmic sperm injection (ICSI) is widely used to improve conception in infertile couples. Embryo cleavage rate is an important laboratory indicator of early embryo development, while sperm morphology may reflect sperm structural and genetic integrity.

Aim: to analyze the association between sperm morphology and embryo cleavage rate in patients undergoing IVF/ICSI.

Materials and Methods. This analytical retrospective study used medical records of infertile couples undergoing IVF/ICSI at Dr. Hasan Sadikin Central General Hospital (Bandung) from January 2020 to December 2024. Patients with complete semen analysis based on World Health Organization (WHO) 2021 criteria and embryo development data up to day 2 post-fertilization were included. Sperm morphology was classified as normospermia or teratozoospermia, and cleavage rate as rapid, normal, or slow. Statistical analysis was performed using the Chi-square test, with odds ratios (ORs) and 95 % confidence intervals (CIs).

Results. A total of 159 records were analyzed. Sperm morphology was significantly associated with cleavage rate (p = 0.001). Teratozoospermia was found in 97.0 % of rapid cleavage cases, 47.3 % of normal cleavage cases, and 93.9 % of slow cleavage cases. Teratozoospermia was associated with higher odds of rapid cleavage (OR = 35.636; 95 % CI = 4.673–271.760) and slow cleavage (OR = 17.261; 95 % CI = 3.903–76.340).

Conclusion. Sperm morphology is significantly associated with embryo cleavage rate in IVF/ICSI. Teratozoospermia may be related to altered timing of early embryo cleavage and may serve as an additional prognostic parameter in IVF/ICSI counseling and laboratory assessment.

Introduction. Malignant neoplasms of the female reproductive system (ovarian, endometrial, and cervical cancers) account for a significant proportion of female oncology morbidity and mortality. Standard treatment methods, including surgery, chemotherapy, and radiotherapy, show limited efficacy in recurrent and drug-resistant tumors. The development of immunotherapy, particularly immune checkpoint inhibitors (ICI), has opened new therapeutic avenues; however, their clinical effectiveness in gynecologic oncology remains suboptimal. In connection with this, it has increased an interest in novel targets, notably TIGIT (T-cell immunoglobulin and ITIM domain), a co-inhibitory receptor expressed on T-cells and natural killer cells (NK-cells), which plays a key role in establishing an immunosuppressive tumor microenvironment.

Aim: to systematize current data on the biological function of TIGIT and relevant ligands, its role in immunosuppression in malignant neoplasms of the female reproductive system as well as evaluate a therapeutic potential of its blockade during a personalized immunotherapy.

Materials and Methods. This review was conducted according to the PRISMA methodology. There was performed a systematic literature search for publications from 2013 to 2024 in the databases PubMed/MEDLINE, Scopus, Web of Science, Embase, Google Scholar, and ClinicalTrials.gov. A total of 91 scientific sources and 7 registered clinical trials were included. Original studies, meta-analyses, reviews, guidelines, and clinical trial reports were analyzed.

Results. TIGIT interacts with several ligands (CD155, CD112, Nectin-4, Fap2), leading to suppression of NK-cells and CD8+ T-cells activity, macrophage polarization toward M2 phenotype, activation of regulatory T-cells (Treg), and impaired antigen presentation. TIGIT is co-expressed with PD-1 (programmed cell death protein 1) and CD96, forming a suppressive signaling network. Its elevated expression is associated with disease progression in ovarian, endometrial, and cervical cancers, reduced cytotoxicity of tumor-infiltrating lymphocytes (TIL), and poor prognosis. TIGIT blockade, especially in combination with PD-1/PD-L1 (programmed cell death ligand 1), restores effector cell function and enhances antitumor immunity in preclinical and clinical studies.

Conclusion. TIGIT is a promising immunotherapeutic target in malignant neoplasms of the female reproductive system. Its blockade may improve treatment outcomes in patients with recurrent and resistant cancert ypes. Combined approaches involving anti-TIGIT agents require further clinical validation but even today they offer new directions in targeted therapy and personalized management in gynecologic oncology.

Sexual dysfunction is one of the most common and underestimated issues observed in women undergone treatment for malignant neoplasms of the female reproductive system. Here, we review current data on the impact of surgical treatment, radiation therapy, and chemotherapy on patients’ sexual health, including symptoms such as vaginal dryness, dyspareunia, decreased sexual desire, and dissatisfaction with intimate life. Special attention is paid to the importance of screening for sexual dysfunction at all stages – from diagnosis to long-term survival. We discuss modern approaches to managing sexual dysfunction, including hormonal and non-hormonal therapies, vaginal moisturizers and lubricants, use of vaginal dilators, pelvic floor physical therapy, psychosocial counseling, and local anesthetic application. The effectiveness of multidisciplinary programs implemented in specialized sexual health clinics is highlighted, along with the growing importance of telemedicine and online resources for patients living in areas with limited access to specialized care. The article also addresses sexual health inequity access to services among marginalized groups, including individuals with low socioeconomic status, residents of rural areas, and members of sexual and gender minority communities. The need to increase awareness among healthcare professionals, integrate sexual health screening into routine oncology practice, and develop individualized rehabilitation programs to improve the quality of women’s life after gynecologic cancer treatment is emphasized.

Aim: to systematize current evidence and analyze the effectiveness of personalized approaches to correcting hemostatic disorders for preventing recurrent pregnancy loss and placenta-mediated complications.

Materials and Methods. A systematic search for publications from 1999 to 2025 was conducted in PubMed/MEDLINE, eLibrary, CyberLeninka, DOAJ (for scientific articles) and FIPS (for patent documents) databases. Using combined MeSH queries, 412 records were initially identified. After removing duplicates and performing multi-stage screening, 63 full-text publications were included in the final analysis. Due to clinical and methodological heterogeneity across studies, a qualitative narrative synthesis of the data was performed.

Results. Hemostatic dysregulation serves as a universal pathogenetic arm in pregnancy loss, manifesting through chorionic villi microthrombosis and placental dysfunction. The combination of acetylsalicylic acid (ASA) 100–150 mg and prophylactic doses of low-molecular-weight heparins (LMWHs) significantly increases live birth rates in antiphospholipid syndrome. It is emphasized that isolated carriage of thrombophilia gene polymorphisms is not an independent indication for LMWHs; their use is pathogenetically and clinically justified only when combined with additional risk factors, such as verified antiphospholipid syndrome (APS), a history of thrombosis, or multiple pregnancy losses. For primary preeclampsia prevention, ASA efficacy at 150 mg initiated at 11–14 weeks of gestational age is well established. The critical importance of preconception administration of active folates for hyperhomocysteinemia correction is confirmed. Integral monitoring via thrombodynamics enables tracking of trimester-specific coagulation changes and personalizing antithrombotic dosing. Sulodexide and dipyridamole demonstrate clinical potential in improving uteroplacental blood flow in fetoplacental insufficiency.

Conclusion. The contemporary management paradigm for these patients requires a shift from empirical regimens to risk stratification and early preconception screening. Optimal clinical strategy is based on evidence-based ASA prescription, strictly differentiated use of LMWHs, folate metabolism correction, and dynamic therapy control using thrombodynamics. The presented data will help minimize iatrogenic complications and define the trajectory for future multicenter studies.

Polycystic ovary syndrome (PCOS) is one of the most common endocrine and metabolic disorders in women of reproductive age, affecting health throughout the lifespan. The etiology of this condition includes genetic factors such as polymorphisms of the CYP11A1, CYP17A1, and DENND1A genes-related epigenetic mechanisms (including promoter methylation of genes associated with steroid hormone synthesis and insulin signaling, as well as the role of microRNAs in regulating folliculogenesis and hyperandrogenism), and environmental cues (diet, stress, and exogenous toxins). Together, these mechanisms lead to dysregulated steroidogenesis, hyperandrogenism, anovulation, and insulin resistance, resulting in heterogeneous clinical phenotypes. The aim of this review is to comprehensively analyze current evidence on the role played by genetic and epigenetic factors in PCOS development and to explore potential application of such findings for improving early diagnosis and developing novel therapeutic approaches.

Aim: to summarize current evidence on reproductive health preservation in women of advanced reproductive age and to present clinically applicable approaches to preconception care, antenatal surveillance, and postpartum management.
Materials and Methods. A review was conducted using publications indexed in PubMed/MEDLINE, eLibrary.ru, CyberLeninka, and Google Scholar from January 2014 to March 2026. Systematic reviews, meta-analyses, clinical guidelines, consensus statements, and original studies addressing age-related reproductive and obstetric risks were analyzed.
Results. Advanced reproductive age is associated with increased risks of preeclampsia, gestational diabetes mellitus, preterm birth, fetal chromosomal abnormalities, and several perinatal complications. However, chronological age alone should not be used as the sole criterion for intensified surveillance. The most clinically relevant care-related components include preconception assessment of reproductive and somatic status, correction of modifiable risk factors, genetic counseling, selection of aneuploidy screening strategy, nutritional support, early preeclampsia risk assessment, screening for gestational diabetes mellitus, and individualized delivery timing.
Conclusion. For women aged 35 years and older, a risk-oriented care model is clinically justified. The scope of assessment and preventive interventions should be determined not only by age but also by ovarian reserve, somatic comorbidity, obstetric history, and early antenatal screening results.

Epilepsy is one of the most common neurological diseases, so that women account for about 50% of patients. The effect of antiepileptic drugs on women's reproductive function is an important and relevant area of medical research. It is now known that many antiepileptic drugs can have significant effects on the reproductive system, affecting both hormone levels and fertility. These effects require careful consideration while choosing therapy for women of reproductive age, especially for those who plan pregnancy or face conception problems. Despite the proven effectiveness for the currently used drugs and their variability, one third of patients achieve no permanent remission of epilepsy. Knowing the pathogenesis underlying development of this disease, in real life, drugs should be used not so much to stop seizures but rather to prevent their emergence. This article examines the mechanisms of action for antiepileptic drugs, their potential impact on reproductive function, and issues related to the management of side effects in clinical practice as well as the individual selection of the most effective and safe therapy.

Autoimmune diseases and pregnancy represent a complex interplay among the immune, vascular, and endocrine systems. Physiological pregnancy is accompanied by dynamic immune adaptation, including the establishment of immunological tolerance, modulation of the Th1/Th2/Th17/Treg balance, and activation of innate immune mechanisms. In autoimmune diseases, these processes may become dysregulated, contributing to endothelial dysfunction, thromboinflammation, complement activation, and placental insufficiency. This review summarizes current concepts on the mechanisms of immune adaptation during pregnancy and the roles of innate and adaptive immunity, microchimerism, the complement system, and neutrophil extracellular traps in the pathogenesis of autoimmune and placenta-associated complications. It also examines the impact of autoantibodies on pregnancy outcomes, including antiphospholipid antibodies as well as anti-Ro/SSA (Ro/Sjögren syndrome-related antigen A), anti-La/SSB (La/Sjögren syndrome-related antigen B), anti-thyroid peroxidase, ANCA (antineutrophil cytoplasmic antibodies), and anti-tissue transglutaminase antibodies. The review discusses the mechanisms underlying preeclampsia, fetal growth restriction, pregnancy loss, and preterm birth, including impaired placentation, endothelial dysfunction, and immunoinflammatory activation. The influence of pregnancy on the course of autoimmune diseases is also considered, including the immunological changes observed in rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus, as well as the role of postpartum reactivation of autoimmune inflammation. Current principles of multidisciplinary pregnancy management for women with autoimmune diseases are presented, including preconception counseling, control of disease activity, safe therapy, and postpartum follow-up. Unresolved issues in reproductive immunology, prospects for identifying biomarkers of pregnancy complications, and the development of personalized approaches to managing patients with autoimmune pathology are also discussed.

Introduction. Antibody-drug conjugates (ADCs) are expanding the therapeutic landscape of systemic treatment for malignancies of the female reproductive system, particularly in the setting of disease progression following standard chemotherapy. Their efficacy is determined by tumor target expression, antibody structure, cytotoxic payload, and drug-to-antibody ratio. However, increased selectivity of delivery does not reduce the risk of systemic and organ-specific toxicity, including adverse events affecting various organs.

Aim: to synthesize data on the clinical significance and safety profile of ADCs currently used or under investigation in ovarian, endometrial, and cervical cancer, with an analysis of the frequency, clinical manifestations, mechanisms, prevention, and management of adverse events.

Materials and Methods. An analytical review of publications on ADCs in gynecologic oncology was conducted, including phase I–III randomized trials, reviews, clinical guidelines, and supportive care documents. Agents targeting folate receptor alpha (FRα), tissue factor (TF), human epidermal growth factor receptor 2 (HER2), trophoblast cell surface antigen 2 (Trop-2), and cadherin-6 were analyzed. The analysis included data on molecular characteristics of the agents, antitumor activity, adverse event frequency, grade ≥ 3 toxicity, organ-specific complications, and safety monitoring approaches.

Results. The most clinically significant ADCs in gynecologic oncology are mirvetuximab soravtansine, tisotumab vedotin, and trastuzumab deruxtecan; promising data have also been identified for Trop-2- and cadherin-6-targeting conjugates. Mirvetuximab soravtansine is characterized by a predominance of ocular complications, largely unrelated to FRα expression in the cornea. Tisotumab vedotin is associated with ocular toxicity, hemorrhagic complications, and peripheral neuropathy, related to tissue factor expression and microtubule-inhibiting payload. For trastuzumab  deruxtecan,  the  most  significant  toxicities  are  gastrointestinal  toxicity, myelosuppression, cardiotoxicity, and drug-induced pneumonitis. Trop-2-directed ADCs are more frequently associated with mucositis, myelosuppression, gastrointestinal disorders, and alopecia. The safety profile of each agent is determined not only by the target but also by the type of cytotoxic payload and dosing regimen.

Conclusion. ADCs occupy an important position in the treatment of malignancies of the female reproductive system; however, their safe use requires individualized risk assessment, patient education, multidisciplinary monitoring, and timely dose modification. Further research should focus on identifying predictors of toxicity, optimizing preventive measures, and developing personalized ADC regimens.

The editors express concern regarding the following review article: Uzdenova D.M., Timofeeva E.A., Isaev D.M., Mestoeva Z.B., Evsikova E.R., Kuznetsova A.A., Zabelin N.V., Kovalenko Yu.V., Kuznetsov D.S., Bembeeva A.E., Monid K.A., Koleukho A.V., Gil U.M. Clinical significance and safety profile of antibody-drug conjugates in malignancies of the female reproductive system. Obstetrics, Gynecology and Reproduction. 2026;20(4):802–819. (In Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2026.769. The reason was doubts about compliance with publication ethics, concerning the authorship and documents authenticity. Currently the editorial board is conducting a revision in accordance with the Committee on Publication Ethics (COPE) recommendations. Until the examination is completed, readers are recommended to interpret the contents of this review taking these circumstances into account.